Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 23586801)

1.

Impact of estradiol valerate/dienogest on work productivity and activities of daily living in women with heavy menstrual bleeding.

Wasiak R, Filonenko A, Vanness DJ, Law A, Jeddi M, Wittrup-Jensen KU, Stull DE, Siak S, Jensen JT.

J Womens Health (Larchmt). 2013 Apr;22(4):378-84. doi: 10.1089/jwh.2012.3633.

PMID:
23586801
2.

Impact of estradiol-valerate/dienogest on work productivity and activities of daily living in European and Australian women with heavy menstrual bleeding.

Wasiak R, Filonenko A, Vanness DJ, Wittrup-Jensen KU, Stull DE, Siak S, Fraser I.

Int J Womens Health. 2012;4:271-8. doi: 10.2147/IJWH.S31740. Epub 2012 Jul 12.

3.

Normalization of blood loss in women with heavy menstrual bleeding treated with an oral contraceptive containing estradiol valerate/dienogest.

Fraser IS, Jensen J, Schaefers M, Mellinger U, Parke S, Serrani M.

Contraception. 2012 Aug;86(2):96-101. doi: 10.1016/j.contraception.2011.11.011. Epub 2012 Jan 10.

PMID:
22240178
4.

Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial.

Fraser IS, Römer T, Parke S, Zeun S, Mellinger U, Machlitt A, Jensen JT.

Hum Reprod. 2011 Oct;26(10):2698-708. doi: 10.1093/humrep/der224. Epub 2011 Jul 21.

5.

Estradiol valerate/dienogest: a novel combined oral contraceptive.

Borgelt LM, Martell CW.

Clin Ther. 2012 Jan;34(1):37-55. doi: 10.1016/j.clinthera.2011.11.006. Epub 2011 Dec 14. Review.

PMID:
22169052
6.

Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest.

Fraser IS, Parke S, Mellinger U, Machlitt A, Serrani M, Jensen J.

Eur J Contracept Reprod Health Care. 2011 Aug;16(4):258-69. doi: 10.3109/13625187.2011.591456.

7.

Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel.

Ahrendt HJ, Makalová D, Parke S, Mellinger U, Mansour D.

Contraception. 2009 Nov;80(5):436-44. doi: 10.1016/j.contraception.2009.03.018. Epub 2009 May 13.

PMID:
19835717
9.

Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial.

Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS.

Obstet Gynecol. 2011 Apr;117(4):777-87. doi: 10.1097/AOG.0b013e3182118ac3.

PMID:
21422847
10.

Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest.

Jensen JT.

Expert Opin Pharmacother. 2010 May;11(7):1147-57. doi: 10.1517/14656561003724713. Review.

PMID:
20367275
11.

Novel oral contraceptive for heavy menstrual bleeding: estradiol valerate and dienogest.

Rafie S, Borgelt L, Koepf ER, Temple-Cooper ME, Lehman KJ.

Int J Womens Health. 2013 Jun 12;5:313-21. doi: 10.2147/IJWH.S31922. Print 2013.

12.

Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM).

Nappi RE, Terreno E, Sances G, Martini E, Tonani S, Santamaria V, Tassorelli C, Spinillo A.

Contraception. 2013 Sep;88(3):369-75. doi: 10.1016/j.contraception.2013.02.001. Epub 2013 Feb 28.

PMID:
23453784
13.

Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial.

Palacios S, Wildt L, Parke S, Machlitt A, Römer T, Bitzer J.

Eur J Obstet Gynecol Reprod Biol. 2010 Mar;149(1):57-62. doi: 10.1016/j.ejogrb.2009.11.001. Epub 2009 Dec 6.

PMID:
19969409
14.
15.

[Association of E2v/DNG as contraceptive choice for a better quality of life of women].

Nappi RE.

Minerva Ginecol. 2012 Feb;64(1):41-52. Review. Italian.

PMID:
22334230
16.

Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life.

Caruso S, Agnello C, Romano M, Cianci S, Lo Presti L, Malandrino C, Cianci A.

J Sex Med. 2011 Oct;8(10):2841-50. doi: 10.1111/j.1743-6109.2011.02409.x. Epub 2011 Aug 2.

PMID:
21810188
17.

Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial.

Raps M, Rosendaal F, Ballieux B, Rosing J, Thomassen S, Helmerhorst F, van Vliet H.

J Thromb Haemost. 2013 May;11(5):855-61. doi: 10.1111/jth.12172.

PMID:
23410231
18.

Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest.

Zeun S, Lu M, Uddin A, Zeiler B, Morrison D, Blode H.

Eur J Contracept Reprod Health Care. 2009 Jun;14(3):221-32. doi: 10.1080/13625180902850039.

PMID:
19565420
19.

Hormone withdrawal-associated symptoms: comparison of oestradiol valerate/dienogest versus ethinylestradiol/norgestimate.

Jensen JT, Parke S, Mellinger U, Serrani M, Mabey RG Jr.

Eur J Contracept Reprod Health Care. 2013 Aug;18(4):274-83. doi: 10.3109/13625187.2013.785516. Epub 2013 May 2.

PMID:
23638631
20.

Efficacy and bleeding profile of a combined oral contraceptive containing oestradiol valerate/dienogest: a pooled analysis of three studies conducted in North America and Europe.

Nelson A, Parke S, Makalova D, Serrani M, Palacios S, Mellinger U.

Eur J Contracept Reprod Health Care. 2013 Aug;18(4):264-73. doi: 10.3109/13625187.2013.780202. Epub 2013 May 7.

PMID:
23651474
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk